The acute intermittent porphyria market is expected to reach $6.33 billion by 2030 at a 6.2% CAGR, driven by novel therapies, genetic diagnostics, and telemedicine adoption.
Read More
The active pharmaceutical ingredients market is set for strong growth, reaching $341.32 billion by 2030 at a 7.0% CAGR, driven by biologics, precision medicine, and contract manufacturing.
Read More
The API intermediate market is projected to grow strongly, reaching $220.78 billion by 2030 at a 7.4% CAGR, driven by CDMO partnerships, reshoring, and pharma R&D expansion.
Read More
The acquired autoimmune hemolytic anemia market is set for strong growth, reaching $3.01 billion by 2030 at a 7.1% CAGR, driven by biologics and advanced diagnostics.
Read More
The acne drugs market is set for steady growth, reaching $7.71 billion by 2030 at a 4.2% CAGR, driven by novel formulations, OTC expansion, and personalized dermatology.
Read More
The acetaminophen-opioid combination market is expected to reach $4.06 billion by 2030 at a 4.9% CAGR, shaped by opioid regulations, stewardship programs, and acute pain management needs.
Read More
The ACE inhibitors market is set for strong growth, reaching $10.11 billion by 2030 at a 6.5% CAGR, driven by personalized care, generics, and digital health adoption.
Read More
The abortion drugs market is poised for rapid growth, reaching $54.85 billion by 2030 at an 11.2% CAGR, driven by telehealth expansion and rising demand for medical abortion.
Read More
Abemaciclib market to reach $2.84 billion by 2030 at 12.1% CAGR, driven by increasing incidence of breast cancer and treatment demand.
Read More
The 3D bioprinted human tissue market is set for rapid growth, reaching $3.59 billion by 2030 at a 13.2% CAGR, driven by regenerative medicine and advanced drug testing.
Read More